News Release

Paper 591 - Blowing Smoke: A Meta-Analysis of Smoking on Fracture Healing and Post-Operative Infection

PHILADELPHIA – Research has long shown the negative effects cigarette smoking has on cardiovascular health. But now, a new study from the Department of Orthopaedic Surgery at the Perelman School of Medicine at the University of Pennsylvania corroborates early evidence showing that cigarette smoking leads to longer healing times and an increased rate of post-operative complication and infection for patients sustaining fractures or traumatic injuries to their bone. The full results of the study are being presented this week at the 2013 American Academy of Orthopaedic Surgeons annual meeting in Chicago.

“Cigarette smoking is widely recognized as one of the major causes of preventable disease in the US, but there has been a lack of evidence showing other side effects of smoking, such as how it changes the way our bones heal,” said Samir Mehta, MD, chief of the Orthopaedic Trauma and Fracture Service at Penn Medicine. “Our study adds substantial support to a growing body of evidence showing that smoking presents a significant risk to fracture patients. These risks need to be addressed with the patient both at the time of injury and when considering surgical treatment.”

Results of the study show that for all injury types, fractured bones in patients who smoke take roughly six weeks longer to heal than fractured bones in a non-smoker (30.2 weeks compared to 24.1 weeks). Additional results show that fractured bones in patients who smoke are 2.3 times more likely to result in non-unions (non-healed fractures) than in non-smokers. 

Using Medline, EMBASE and Cochrane computerized literature databases, the researchers collated previous studies that have examined the effects of smoking on bone and soft tissue healing. By analyzing these studies, the team sought to find an association between smoking and healing time, and various complications such as post-surgical infection. Studies included in the analysis focused on fractures of the tibia, femur or hip, ankle, humerus, and multiple long bones. In total, 6,480 patient cases (treated both surgically and non-surgically) were evaluated in the studies.

With approximately 6.8 million fractures requiring medical treatment in the US annually, the researchers say the overall burden of musculoskeletal disease is substantial. Though recent efforts have been made to promote bone health through vitamin and mineral supplements and nutritional support, the research team says that altering social factors such as encouraging smoking cessation have been under-addressed. This void is causing both a disconnect in the short-term treatment for patients and a missed opportunity to improve long-term health.

“The effects of smoking intervention programs need to be discussed and instituted to promote better outcomes for post-fracture patients,” says Mehta. “We have an opportunity to help patients understand that it’s about more than just heart health, and that smoking puts you at a higher risk of complications and leads to longer healing times.”

The research team says future studies are needed to evaluate the dose-dependent effects of smoking on fracture healing. In addition, the increasing use and production of smokeless tobacco presents new questions about the effects of nicotine, and other tobacco products, through non-combustable forms. Finally, studies that better delineate the impact of directed education and the effects of the timing of smoking cessation (both before and after surgery) on the post-operative complication rate are also needed to provide the best care for fracture patients.

Lead author on the study is Jaimo Ahn, MD, assistant professor of Orthopaedic Surgery at Penn Medicine. Other Penn authors include Mara L. Schenker, MD, John A. Scolaro, MD, Sarah M. Yannascoli, MD, and Keith D. Baldwin, MD. Results of the study were presented at AAOS by Dr. Schenker.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

Share This Page: